ID :
175501
Thu, 04/14/2011 - 18:22
Auther :
Shortlink :
https://oananews.org//node/175501
The shortlink copeid
STEMPEUTICS STARTS MALAYSIA'S FIRST CLINICAL TRIAL ON STEM CELL BASED IND
KUALA LUMPUR, April 14 (Bernama) -- Stempeutics Research Malaysia Sdn Bhd
has been granted approval from Malaysian authorities to conduct clinical trials
on stem cell based investigational new drugs (IND).
Its Country Manager Madhu Kumar said the approval came at the right time,
with Malaysia entering the second phase of the national Biotechnology
Policy which focuses on commercialisation, from 2011 to 2015.
"The IND has been developed based on international standards under stringent
quality processes.
"There will be continuous research for each disease so as to improve product
development for effective therapy," he said at a press conference here Thursday.
Stempeutics, an international company under the Manipal Education and
Medical Group was given the BioNexus status by Malaysian Biotechnology Corp
(BiotechCorp) in 2007, Malaysia's lead development agency for the biotech
industry.
This marks a new development for Malaysia, and "we are the only country,
other than the United States and India, going through this groundbreaking phase
in stem cell based research," said Iskandar Mizal Mahmood, Chief Executive
Officer of BiotechCorp.
He said the regenerative medicine area in biomedical research was rapidly
emerging with therapeutic potential worldwide.
"We should be aware that this particular field is new, not only here in
Malaysia but also in developed market like United states."
Iskandar added the global market for stem cell therapy was expected to be
at RM16 billion (US5.33 billion) in 2014. In Malaysia the market for stem cell
therapy is RM157 million (US$52.33 billion).
He said it was necessary to explore the full potential of stem cell to
transform biomedical therapy as it would significantly enhance medical treatment
in Malaysia.
Based on the successful outcome of the clinical trial, Stempeutics has
plans to introduce its first stem based drug which is aimed to be available
in Malaysia in the near future.
has been granted approval from Malaysian authorities to conduct clinical trials
on stem cell based investigational new drugs (IND).
Its Country Manager Madhu Kumar said the approval came at the right time,
with Malaysia entering the second phase of the national Biotechnology
Policy which focuses on commercialisation, from 2011 to 2015.
"The IND has been developed based on international standards under stringent
quality processes.
"There will be continuous research for each disease so as to improve product
development for effective therapy," he said at a press conference here Thursday.
Stempeutics, an international company under the Manipal Education and
Medical Group was given the BioNexus status by Malaysian Biotechnology Corp
(BiotechCorp) in 2007, Malaysia's lead development agency for the biotech
industry.
This marks a new development for Malaysia, and "we are the only country,
other than the United States and India, going through this groundbreaking phase
in stem cell based research," said Iskandar Mizal Mahmood, Chief Executive
Officer of BiotechCorp.
He said the regenerative medicine area in biomedical research was rapidly
emerging with therapeutic potential worldwide.
"We should be aware that this particular field is new, not only here in
Malaysia but also in developed market like United states."
Iskandar added the global market for stem cell therapy was expected to be
at RM16 billion (US5.33 billion) in 2014. In Malaysia the market for stem cell
therapy is RM157 million (US$52.33 billion).
He said it was necessary to explore the full potential of stem cell to
transform biomedical therapy as it would significantly enhance medical treatment
in Malaysia.
Based on the successful outcome of the clinical trial, Stempeutics has
plans to introduce its first stem based drug which is aimed to be available
in Malaysia in the near future.
